Of note, analysis of tissues CRC patient tumor samples revealed that low eEF2K activity has been associated with a worse prognosis of patients [33, 34], indicating that stratifying patients by developing robust pharmacological biomarkers relating to translation elongation may enable more personalised treatment options for cancer patients. The gene discussed is EEF2K; the disease is colorectal carcinoma.